WP
PRME icon

Woodline Partners’s Prime Medicine PRME Stock Holding History

Woodline Partners’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5M Buy
3,003,313
+469
+0% +$1.78K 0.04% 500
2025
Q4 		$10.4M Buy
3,002,844
+362
+0% +$1.61K 0.04% 455
2025
Q3 		$16.6M Buy
+3,002,482
New +$12.2M 0.08% 323
2024
Q1 		– Sell
-120,060
Closed -$1.06M – 615
2023
Q4 		$1.06M Buy
+120,060
New +$925K 0.01% 403

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Woodline Partners's PRME Position: Q1 2026 in Review

Woodline Partners increased its Prime Medicine (PRME) stake by 0.02% in Q1 2026, buying an estimated $1.78K and bringing the position to 3,003,313 shares worth $10.5M. The position accounts for 0.04% of the portfolio, ranked #500.

Woodline Partners first reported a position in PRME in Q4 2023 and has held it in 4 quarters since. The position peaked at $16.6M in Q3 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Woodline Partners held 3,003,313 shares of Prime Medicine worth $10.5M as of Q1 2026.
  • Woodline Partners bought 469 Prime Medicine shares in Q1 2026, an estimated $1.78K.
  • Prime Medicine made up 0.04% of Woodline Partners's portfolio in Q1 2026, its #500 holding.
  • Woodline Partners first reported a position in Prime Medicine in Q4 2023 and has held it in 4 quarters since.
  • Woodline Partners's Prime Medicine position peaked at $16.6M in Q3 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.